BRCA2 and ovarian carcinoma: Additionally, the increased presence of BRCA2 variants in ovarian cancer from the cancer-specific analysis showed trending significance in the traditional PheWAS (phecode 184.11, “malignant neoplasm of ovary”, p = 1.6 × 10−3, OR = 32) (Figures 2A and 2C).